LeadStory

CNBC

Viking Therapeutics plummets on new obesity drug data

CNBC · Current
CNBC
CNBC
Current

Shares of Viking Therapeutics plunged Tuesday after the company released midstage trial data on its obesity pill that disappointed investors. CNBC’s Angelica Peebles joins 'Money Movers' to discuss.

Breakdown
  • Viking Therapeutics' shares dropped over 40% after new obesity drug trial data was released. 1s
  • Trial participants lost about 12% of body weight at the highest dose over three months. 18s
  • 28% of participants stopped taking the drug, with 20% discontinuing due to side effects, mainly nausea. 27s
  • Analysts question the drug's competitiveness and Viking's potential as a major market player. 54s
  • Uncertainty remains about the future demand for oral obesity drugs amid strong competition. 1m 49s
BusinessMedical ResearchStockmarket